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ABSTRACT
The

aim

recommended

of
lab

the

study

monitoring

is
for

to

determine
metformin

whether
is

the

performed

appropriately in the ambulatory care setting and if the patient
characteristics are associated with monitoring rate. A cross-sectional
study was performed using a healthcare claims database. An
univariate analysis by frequency and percentage assessed the
characteristics of patients in our study. Also, it measured the
frequency of lab monitoring: HgbA1C, CBC or B12, SCR, and optimal,
defined as receiving all three tests. Bivariate analyses determined the
significance of differences between those receiving and not receiving
lab testing according to patient characteristics. In a prediction model,
multivariate

logistic

modeling

with

backward

elimination

was

performed to identify significant patient characteristics predicting lab
monitoring, and to obtain adjusted odd ratios. Optimal lab monitoring
rate during 18 months rate during the 18 month was 32.88 percent. A
predictive

model

included

age

category,

cardiovascular,

renal,

respiratory disease, mental health disorder, number of clinic visit, and
medication possession rate (MPR). Elderly patients with comorbidities
were more likely to receive optimal care; more frequent clinic visits
and greater rates of medication adherence were associated with
receiving optimal lab monitoring for metformin.
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CHAPTER 1

BACKGROUND

Diabetes Mellitus is a global epidemic which affects 8.3% of the
United States’ population, or 25.8 million in 2010.1 In 1980, the
number of persons diagnosed with diabetes in America was 5.6 million
which increased to 20.9 million in 2012.1 Globally, the incidence of
diabetes is increasing dramatically, caused by more urbanization,
obesity, and longer-life expectation for patients with diabtes.2 Rising
number of these patients with diabetes also leads to growing
expenditure of diabetes care which had become a great burden to the
American society. From 2002 to 2007, the total cost of diabetes has
increased from $132 billion to $174 billion.3
High expenditure is associated with various complications from
diabetes such as retinopathy, nephropathy, coronary artery disease,
peripheral artery disease and cerebrovascular disease. Diabetes is the
leading cause of a kidney failure. In 2008, diabetes was accountable
for 44% of new cases of a kidney failure.4 About 60 to 70% of
patients with diabetes have mild to severe forms of nervous system
damage and they are twice as likely to have depression than people
1

without diabetes.5, 6 In addition to the complications, this population is
often obese and has a high cholesterol level and blood pressure.
Therefore, other comorbid, metabolic diseases coexist in patients with
diabetes; such comorbidities increase the cost of care and complicate
patients’ drug regimen. Such complex drug regimen and vulnerability
of patients with diabetes are significant problems for their care.
According to the current American Diabetic Association (ADA)
guidelines for diabetes, metformin is a preferred first-line treatment
for the treatment naïve patients with diabetes type II.7 Metformin use
is prevalent and its safety and effectiveness has been well
demonstrated. Hypoglycemia occurs less frequently with metformin
than any other oral antidiabetic medications. The common side effects
are diarrhea, flatulence, cobalamine deficiency, and asthenia. Serious
side effects include lactic acidosis yet this condition is very rare, at
0.03 cases per 1000 patients years.8, 9, 10 Although metformin is a
fairly safe drug, laboratory monitoring is recommended to avoid
anemia, lactic acidosis, or other complications. Vitamin B12 level is
recommended to be monitored every 2-3 years and hematologic
parameters should be monitored at the baseline and annually to avoid
anemia.8,9 Also, renal function test (Serum Creatinine, Scr) before
initiation and annually thereafter is recommended to monitor the risk
2

of lactic acidosis. Since a substantial amount of metformin is excreted
through kidney, monitoring Scr level is prudent. Additionally,
glycosylated hemoglobin (HbA1C) level testing monitors efficacy of
the drug; it is also a safety measure to monitor hypoglycemia or to
delay or avoid further complication of diabetes.8, 9
In practice, however, metformin is often used without safety
monitoring given its reputation for safety. A retrospective study of
metformin use in inpatient setting presented that among 204
hospitalized metformin users, 27% had at least one absolute
contraindication to metformin.10 The most common contraindication
was elevated serum creatinine concentration in 32 patients (12%).
However, metformin was discontinued in only 8 (25%) of these
patients. The disconnection of clinical guideline for metformin use and
real practice was found in outpatient setting as well. A cross-sectional
analysis, conducted in 10 different HMOs, reported that the absence
of Scr lab testing at the initiation of metformin therapy was 25.8% (95%
CI 15.2-35.9).11 Also, another cross-sectional study with chronic
metformin users reported the rate of missing annual Scr testing by
29%, 26%, 25% in 1999, 2000, 2001, respectively.12 Cell blood count
testing was missing more frequently, 80%, 79%, 78% in 1999, 2000,
2001, respectively.
3

Several studies had examined how recommended monitoring is
practiced in a clinical setting. However, no studies have examined
metformin users specifically and variables that may be associated with
suboptimal monitoring. The increasing diabetes population and lower
safety awareness for metformin necessitates careful assessment of
metformin safety laboratory screening. Therefore, we conducted this
study to determine how the practice of laboratory monitoring for
metformin reflects recommended guidelines. Also, patient
characteristics that are potentially associated will be identified to
highlight barriers to those safety measures. We hypothesize that lab
monitoring for metformin will be suboptimal and may be associated
with specific patient characteristics.
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CHAPTER 2

METHODS

A cross-sectional observational study was performed using a
claims database from a large commercial insurance plan. Data
included members with diabetes and described members’ membership
status, demographic information, medical diagnosis, laboratory testing,
medication dispensing, and healthcare utilization. The claims data
included medical utilization data spanning from January 1, 2008 – May
31, 2010.
Inclusion criteria for the study population were a minimum of
18 years of age, diagnosed with diabetes according to ICD-9 code,
having 18 months of continuous enrollment, and at least two
metformin dispensing during the study frame. Also, patients were
required to have three months before and after the study period to
capture patients who may receive delayed annual lab monitoring. If
members were hospitalized during the study period, they were
excluded because all hospitalized patients would receive lab
monitoring and therefore the results could be biased.
We hypothesized that laboratory monitoring for metformin
5

would be suboptimal and would vary according to patient
characteristics. The main study outcome determined if metformin
users with diabetes diagnosis received recommended safety lab
monitoring for metformin. The manufacturer of metformin
recommends that patients receive at least once yearly monitoring of
glycosylated hemoglobin (A1C), anemia monitoring which includes
either cell blood count (CBC) or vitamin B12 (B12) level, and serum
creatinine level (SCR) which indicates patients’ renal status. Members
were considered to have optimal safety monitoring if they received all
of the three lab tests.
The 2009 Healthcare Effectiveness Data and Information Set
(HEDIS) standards and Current Procedure Terminology (CPT) codes
served as a reference for identifying A1C, CBC, B12, and SCR from
chemistry 7 tests. Common Procedural Terminology (CPT) codes were
reviewed to identify any hospitalization and the number of clinic visits
throughout the study period. The International Classification of
Disease 9 (ICD 9) was used to confirm a diabetes diagnoses for each
member and to identify comorbidities including cardiovascular disease,
respiratory disease, mental disease, and renal disease. Cardiovascular
disease included heart failure, hypertensive heart disease, myocardial
infarction, angina, and atherosclerosis. Respiratory disease included
6

bronchitis, emphysema, asthma, and chronic obstructive pulmonary
disease. Mental health disorders included bipolar, paranoid, psychosis,
autism, personality disorder, depression, conduct disorder and
attention deficit hyperactivity disorder. Lastly, renal disease included
hypertensive chronic kidney disease, renovascular hypertension, cystic
kidney disease, renal dysplasia, kidney transplant, renal dialysis, acute
kidney failure, and glomerulonephritis.
Additionally, the frequencies of A1C, CBC, B12, SCR, and
optimal lab monitoring performed were stratified into three different
study periods: 12, 15, and 18 months. The frequency of each lab
monitoring was to compare the difference among study length and
allowing additional time of screening.
Descriptive statistics of the final cohort included age group,
gender, diabetes medication use, comorbidities, and level of
healthcare utilization. Diabetes medication use was classified
according to the type of metformin product dispensed (sole ingredient
vs. combination) and by insulin use. The comorbidities were classified
as cardiovascular, respiratory, mental and renal diseases. Healthcare
utilization measured five different components: the number of
prescriptions dispensed during the baseline period (three months
before the index date), the total cost of medication per month during
7

the screening period, the number of clinic visit and medication
adherence rate throughout the study period. The frequencies of A1C,
CBC, B12, SCR, and optimal monitoring performed were also
measured in the final cohort. Descriptive statistics presented the
frequencies and percentages for all variables assessed.
For these categorical variables, chi-square tests were
performed to determine statistical significance of differences in
proportions, according to the optimal lab monitoring outcome
variables. These categories included age group, gender, types of
diabetes medication use, comorbidities, and level of healthcare
utilization. Multi-colinearity between these independent variables was
examined by a correlation matrix and diagnostics, while the
interaction among the independent variables was explored using
multivariate logistic modeling.
Predictive models for optimal lab monitoring were built using
multivariate logistic regression with a backward elimination process.
All variables were first included and statistically insignificant
independent variables (P>0.05) were eliminated from the model step
by step. The Hosmer-Lemshow goodness of fit test assessed the
validity of the model. The significant independent variables in the
8

model were reported as an adjusted odds ratio with corresponding 95%
confidence intervals.
Data analysis was performed using SAS (version 9.3).

9

CHAPTER 3

RESULTS

A total of 7068 members were selected from 14,908 members
in the claims database (see flowchart). The sample population had a
mean age of 63.1 years with a standard deviation of 12.16 (table 1).
The distribution of age was highest in 40-64 year old group, 57.4
percent, and was second highest in the 65-79 year old group, 30.74
percent. The remaining age groups 18-39 year and 80 and older
contributed 2.45 percent and 9.32 percent of the distribution,
respectively. The percentages of male and female patients were 54.56
and 45.44 percent, respectively. A majority of members used
metformin as a sole ingredient product, 84.80 percent. Only 19.95
percent of members were using insulin. The cohort members received
average of 4.8±2.94 prescriptions during three months before the
study enrollment, and the median cost of the medication per month
was $20.64. The cohort members visited a doctor’s office an average
of 10.08±6.19 times throughout the study. The average Medication
Possession Rate (MPR) was 85.06±20.82 percent.
During the 18 month study period, the recommended lab
10

monitoring for metformin such as HgbA1C testing, CBC, Vitamin B12,
and Scr were performed in 75.44, 43.15, 10.98 and 52.57 percent of
the cohort members. Members who received optimal monitoring
(HgbA1c, CBC or B12, and Scr) were only 32.88 percent. The percent
of optimal lab monitoring improved with longer period of assessment:
12 months 26.1%, 15 months 29.2% and 18 months 32.9% (table 2).
In the bivariate analyses, HgbA1C, Anemia Test (CBC or B12),
Scr, and Optimal tests revealed statistically significant differences
among age groups (P<0.0001) (table 3). The patients in the oldest
group were more likely to receive lab monitoring as compared with
younger patients. Males received less frequent lab testing of any kind
as compared with females (HgbA1C, Anemia Test, SCR, Optimal,
respectively, P<0.0001, P<0.0001, P=0.0002, P<0.0001). Insulin-use
was associated with greater frequency of HgbA1C testing, with
statistically significant differences as compared to non-insulin-user
(P=0.0254). Patients with respiratory, cardiovascular, or renal disease
were more likely to receive any type of lab monitoring performed as
compared with patients no having these conditions. Unexpectedly,
patients with mental health disorders had significantly higher number
of optimal lab performed than patient without mental illnesses
(p=0.0281). All health utilization components demonstrated
11

statistically significant differences among different categories. A higher
number of prescriptions and higher cost of medication at baseline and
higher number of clinic visits were associated with increased lab
monitoring. Medication adherence was also associated with frequent
lab monitoring (P<0.0001). Monitoring did not differ according to the
type of metformin product utilized.
The logistic regression model for renal function testing revealed
that age, cardiovascular disease, renal disease, number of clinic visits,
and medication adherence were significant in fitting the prediction
model (table 4). Patients in age category 4 (age 80 and over) were
approximately four times more likely to receive serum creatinine
testing as compared with those in age category 2 (40-65 year of age)
(OR 4.007, 95%CI 3.292-4.877). Cardiovascular disease and renal
disease also contributed to more frequent lab monitoring for
metformin than patients with no such comorbidities. Patients with
more than 14 clinic visits were almost 50 percent more likely to
receive Scr testing than patients with 7-9 clinic visits (OR 1.489, CI95%
1.287-1.722). The variable for medication adherence was not
significant in this analysis, and was thus excluded from the model.
The logistic regression model assessing anemia testing which
reflected either a CBC or B12 test at least once yearly, included
12

gender as a significant independent variable (table 5). Unlike the
other models, anemia testing was associated with gender. Female
patients were 15 percent more likely to receive anemia tests than
male patients (OR 1.151, 95%CI 1.042-1.270). Otherwise, this
second model was similar to the previous model described above.
Elderly people and patients with more frequent visit to clinic were also
more likely to receive lab monitoring for anemia.
The model for HgbA1C testing included age, gender, insulin use,
renal disease, and the number of clinic visits (table 6). The oldest age
category was eight times more likely to receive HgbA1C testing than
age category 2 (OR 8.283, 95%CI 5.816-11.797). Among the
different labs for metformin, HgbA1C testing was most significantly
associated with older age. HgbA1C testing was also associated with
insulin use (OR 1.198, 95%CI 1.036-1.384).
Finally, the predictive logistic regression model for optimal
monitoring performed included 7 variables: age group, cardiovascular
disease, nephropathy, respiratory disease, mental health disorder,
number of clinic visits, and medication adherence rate (table 7). No
co-linearity was found between these independent variables, yet there
was an interaction between category clinic visit3 (10-13) and
respiratory disease. The interaction term was included in the model
13

originally because of its statistical significance with the outcome
variable. However, ultimately, it was removed in a backward
elimination step because the interaction term did not significantly
affect the logistic model fit.
According to the final model, patients in age group of 65-80
year were 2 times more likely and those 80 year and over were 3
times more likely to receive optimal lab monitoring for metformin than
age group of 40-65 year, odd ratios of 2.228 (95% CI 1.983-2.503)
and 3.204 (95%CI 2.685-3.8230). When patients had other comorbid
diseases such as cardiovascular disease, renal disease, respiratory
disease or mental health disorders, such patients were more likely to
receive optimal lab monitoring for metformin. The odd ratios of
cardiovascular disease, renal disease, respiratory disease and mental
disease were 1.190 (95% CI 1.053-1.344), 1.559 (95% CI 1.2981.872), 1.205 (95% CI 1.040-1.396), and 1.194 (95% CI 1.0301.384), respectively. In assessing level of health utilization, the cohort
members who visited the clinic less than 6 times throughout a year
were 23 percent less likely to receive optimal lab monitoring than
members who visited 7-9 times (OR 0.774, 95%CI 0.667-0.898). The
members who visited more than 14 times were 94 percent more likely
14

to receive optimal lab monitoring than members who visited 7-9 times
(OR 1.935, CI95% 1.664-2.250). Lastly, patients who had a
medication adherence rate of 0-69 percent were less likely to receive
optimal care than patients who had adherence rate of 80-89 percent
(OR 0.769, CI95% 0.617-0.957). As expected, higher medication
adherence rate was associated with a greater frequency of optimal lab
monitoring. Also, Hosmer and Lemeshow Goodness-of-Fit test
reported a Chi-square of 6.4535; p=0.5966. There were no
statistically significant differences between predictive and observed
value, therefore, confirming the fitness of our modeling.
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CHAPTER 4

DISCUSSION

Adverse drug events are unwanted effects from medications
and many are preventable or treatable. A cohort study of Medicare
enrollees conducted by Gurwitz JH et al in 2003 examined adverse
events occurring in the ambulatory setting. The researcher reported
that 27.6 percent of 1523 adverse drug events were preventable.
Errors associated with adverse drug events occurred most commonly
in the monitoring stage (60.8%), which was higher than errors of
patient adherence (21%) or in prescribing stages (58.4%).14 In
another study based on a systemic review of adverse medications
events, Smith DH et al also reported that 21 percent of adverse
events were preventable, with inadequate monitoring accountable for
45.4 percent of the drug therapy problems requiring hospital
admission.15 Monitoring medication therapy is an important aspect of
the patient care process and it is inadequately performed according to
current literature.
This study examined the rate of optimal lab monitoring for
metformin and attempted to identify the metformin users who are
16

more likely to receive appropriate safety monitoring. We failed to
reject our stated hypothesis that monitoring in practice is suboptimal
and associated with patient characteristics. The rate of lab monitoring
for metformin was less frequent than clinically indicated, and varied
according to patient characteristics. Only 32.9 percent of patients
received optimal safety monitoring for metformin. The rate of HgbA1c,
CBC, B12, and Scr tests, were 75.4%, 43.2%, 11.0%, and 52.6%,
respectively. The creatinine monitoring rate was lower than previous
literature has reported.12.13l This difference might be explained by the
difference in data source, as Hurley et al used data from Health
Maintenance Organizations (HMOs) having a larger number of
observations and more complete information about patient care. Also,
The Rabael et al study only looked at initial monitoring for metformin.
Ongoing monitoring of metformin is expected to be less than initial
monitoring. Interestingly, CBC rate was higher in our study members
than other populations. The result might be caused by higher average
age of our study patients compared with Hurley et al (63.1 vs. 57.8
year old).13
According to the bivariate analyses, all independent variables
except type of diabetes medication use and the status of insulin use
were associated with optimal lab monitoring performed. In addition,
17

multivariate logistic regression modeling revealed that several
independent variables significantly impacted the performance of
optimal monitoring. Those variables were age group, comorbidities,
number of clinic visit and medication adherence rate.
The older age groups 65-80 year of age and 80 over were
more likely to receive optimal safety monitoring while younger groups
40-65 were less likely. Cardiovascular disease, renal disease, mental
disease, respiratory disease may have brought more attention from
practitioners and revealed the association with higher possibility of
optimal lab monitoring performed. In particular, patients with renal
disease were 50 percent more likely to receive optimal care than
patient without renal disease (OR 1.559, 95%CI 1.298 and 1.872).
The group with 14 or more clinic visits was nearly twice as likely to
receive optimal care as the group having 7-9 clinic visits. The patients
with lower medication adherence rate than 70 were 23 percent less
likely to have optimal monitoring than patients with an 80-89 percent
adherence rate. High medication possession rate may represent high
health awareness of patients (self-motivated) and be associated with
more routine clinic visits.
Other multivariate models for Scr, CBC or B12, and HgbA1c
were similarly affected by age, renal disease, and number of clinic
18

visits. Interestingly, gender was a statistically significant variable in
the models assessing testing for CBC or B12 and HgbA1C. Females
were more likely to receive an anemia test, given the higher
prevalence of this condition in female patients. Yet, HgbA1C test
cannot be explained by different disease prevalence, and it is
uncertain why females appeared to receive indicated monitoring more
frequently.
Overall, the recommended lab monitoring for metformin was
not optimally executed in practice. The metformin users with diabetes
were more likely to receive optimal lab monitoring if they were elderly
with cardiovascular, renal, respiratory or mental disease, visited the
clinic more than 14 times in a year and demonstrated a high
adherence rate with medication. Conversely, healthcare providers
have to focus on monitoring younger patients with fewer
comorbidities who do not visit the clinic as often, and having lower
adherence to medication. Such patients are easiest to be missed in
care because healthcare encounters are infrequent and typically focus
on acute medical needs. Recently, pharmacy lab monitoring alert
systems and other interventions have been explored as a means to
increase monitoring toward optimizing the safety of care.16 However, a
first step is for healthcare providers to recognize that metformin lab
19

motoring is suboptimal, and that relatively healthier patients may be
more likely to miss required laboratory monitoring. Furthermore, it is
important that providers recognize the importance of lab monitoring
as an important process to promote safe medication use.
Several limitations of this study exist. First, the study was
conducted in claims database that is specific to one disease state and
the study period spanned only 18 months. It is not possible to
generalize our results to larger populations, yet our sample
represented typical diabetes patients using metformin. Secondly, the
all-or-none approach to our assessment of optimal lab monitoring
performed may been overly strict considering typical medical practice.
Recommended monitoring for metformin may be overly excessive and
impossible to implement. Third, the study data have particular
limitations. The claims database was compiled based on the paid
claims. Therefore, any diagnosis, procedure, and pharmacy data that
was not recorded or paid out-of-pocket was missed. Also, the results
could have been biased by patients’ other comorbidities or
medications that can influence prescribers to order labs. In this study,
we examined interaction with comorbidities and age to account for
this bias.
Some may argue that another limitation to this study is the fact
20

that metformin is considered to be very safe pharmacotherapy. For
example, several literature has been published that rebukes the
association of lactic acidosis with metformin use17., 18. However,
monitoring guidelines and recommendations should ideally match
practice regardless of the perceived degree of the true risk. In general,
patients are all at risk of taking medication and usually risks are
unknown. Therefore, healthcare providers must follow the guidelines
for safety monitoring to protect their patients, even though it might
feel unnecessary or ineffective. The roles of government and
researchers are to make a precise and practical guideline for periodic
medication safety lab monitoring. Everyone together should make
every effort to protect patients from harm and prevent unnecessary
hospitalization and death.
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FIGURE 1
SAMPLE SELECTION FLOWCHART

21 153 Initial Cohort

15 214 Metformin Users
1 712 Enrollment≤18-Mos
13 502 18-Months
Continuous Enrollment
4 080 <3-Mo Pre/post Index
date
9 422 3-Months Before &
After Index Date
1 378 NonPersistent User
8 044 At Least Two
Metformin Dispensing
128 No Diagnosis
of Diabetes
7 916 Diabetes Diagnosis
250.XX

847 Hospitalized

7 069 Nonhospitalized
1 Age < 18
7 068 Age >= 18
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TABLES
Table 1: Characteristics of the Study Sample
Variable

Cohort (n=7068)

Age, years
Mean

63.1±12.2 (18 - 99)

18 - 39

173 (2.45%)

40 – 64

4063 (57.48%)

65 – 79

2173 (30.74%)

80 and more

659 (9.32%)

Gender
Male

3856 (54.56%)

Female

3212 (45.44%)

Diabetes Medication Use
Metformin Mono-product

5994 (84.80%)

Metformin Combination Product

1074 (15.20%)

Insulin Dependent(Use)

1410 (19.95%)

Insulin Independent(No Use)

5658 (80.05%)

Co-morbidity
Respiratory

981 (13.88%)

Cardiovascular

1753 (24.80%)

Mental Health Disorder

1038 (14.69%)

Nephropathy

568 (8.04%)

Healthcare Utilization
Number of Prescriptions at Baseline (Three months period before the index date)
Mean

4.8±2.94 (1 – 28)

0–2

1636 (23.15%)

3

1111 (15.72%)

4–5

1928 (27.28%)

6 – 28

2393 (33.86%)

Total Cost of Medications Per Month
Median(Dollar $)

20.64 (0 - 538.83)

0 – 5.2

1769 (25.03%)

5.3 – 11.7

1773 (25.08%)
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Table 1: Characteristics of the Study Sample Continued
11.8 – 26.7

1769 (25.03%)

26.8 – 538.8

1757 (24.86%)

Number of Clinic Visit During the Study Period (During 18 months)
Mean

10.08±6.19 (0 – 76)

0–6

2201 (31.14%)

7–9

1718 (24.31%)

10 – 13

1580 (22.35%)

14- 76

1569 (22.20%)

Level of Adherence (Medication Possession Rate %)
Mean

85.06±20.82 (5 – 100%)

90 – 100

4420 (62.54%)

80 – 89

547 (7.53%)

70 – 79

532 (7.63%)

0 – 69

1569 (22.20%)

Lab Monitoring(During 18 months)
A1C

5332 (75.44%)

CBC

3050 (43.15%)

B12

776 (10.98%)

Renal Screening (Scr)

3716 (52.57%)

Optimal*

2324 (32.88%)

Optimal* recommend lab monitoring for metformin is to complete HgbA1C, CBC or
B12, and renal function test (SCR) annually.
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Table 2: Frequency of Laboratory Monitoring Performed Based According to 12, 15,
and 18 Month Intervals
12 Months

15 Months

18 Months

Optimal Lab

1841 (26.1%)

2067 (29.2%)

2324 (32.9%)

HgbA1C

5072 (71.8%)

5201 (73.6%)

5332 (75.4%)

CBC

2561 (36.2%)

2810 (39.8%)

3050 (43.2%)

B12

606 (8.6%)

683 (9.7%)

776 (11.0%)

SCR

3304 (46.8%)

3490 (49.4%)

3716 (52.6%)
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Table 3: Performance of Recommended Laboratory Monitoring During the 12 Month
Study Period According to Patient Characteristics.
Variable

Hgb

A1C

CBC

or

B12

Renal Function

Optimal*
Monitoring

testing

Testing

Test

(n=5332)

(Anemia Test)

(n=3716)

(Scr)

(n=3233)

Performed
(n=2324)

N (%)

N (%)

N (%)

N (%)

18-39

121 (2.3%)

65 (2%)

63 (1.7%)

38 (1.6%)

40-64

2734 (51.3%)

1500 (46.4%)

1715 (46.2%)

981 (42.2%)

65-79

1852 (34.7%)

1227 (38%)

1431 (38.5%)

952 (41%)

80 and more

625 (11.7%)

441 (13.6%)

507 (13.6%)

353 (15.2%)

P<0.0001

P<0.0001

P<0.0001

P<0.0001

Male

2817 (52.8%)

1649 (51%)

1949 (52.4%)

1191 (51.2%)

Female

2515 (47.2%)

1584 (49%)

1767 (47.6%)

1133 (48.8%)

P<0.0001

P<0.0001

P=0.0002

P<0.0001

4517 (84.7%)

2735 (84.6%)

3140 (84.5%)

1957 (84.2%)

815 (15.3%)

498 (15.4%)

576 (15.5%)

367 (15.8%)

P=0.7124

P=0.6541

P=0.4516

P=0.3282

1096 (20.6%)

645 (20%)

765 (20.6%)

485 (20.9%)

4236 (79.4%)

2588 (80%)

2951 (79.4%)

1839 (79.1%)

P=0.0254

P=0.9978

P=0.1579

P=0.1755

768 (14.4%)

515 (16%)

589 (15.9%)

407 (17.5%)

P=0.0255

P<0.0001

P<0.0001

P<0.0001

1423 (26.7%)

949 (29.4%)

1109 (29.8%)

753 (32.4%)

P<0.0001

P<0.0001

P<0.0001

P<0.0001

Age, years

Gender

Diabetes Medication Use
Metformin
Mono-product
Combination
product
Insulin
Dependent(Use)
Independent
(No Use)
Co-morbidity*
Respiratory

Cardiovascular
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Table 3: Performance of Recommended Laboratory Monitoring During the 12
Month Study Period According to Patient Characteristics. Continued
Mental Disease
Nephropathy

767 (14.4%)

499 (15.4%)

554 (14.9%)

372 (16%)

P=0.2101

P=0.1025

P=0.5778

P=0.0281

480 (9%)

351 (10.9%)

386 (10.4%)

279 (12%)

P<0.0001

P<0.0001

P<0.0001

P<0.001

Health Utilization
Number of Prescriptions at Baseline (Three months period before the index date)
0–2

1199 (22.5%)

679 (21%)

815 (22%)

462 (19.9%)

3

796 (14.9%)

451 (14%)

541 (14.6%)

314 (13.5%)

4–5

1482 (27.8%)

895 (27.7%)

1013 (27.3%)

640 (27.5%)

6 – 28

1855 (34.8%)

1208 (37.4%)

1347 (36.2%)

908 (39.1%)

P=0.0001

P<0.0001

P<0.0001

P<0.0001

Total Cost of Medications Per Month
$0 – 5..2

1250 (23.4%)

722 (22.3%)

838 (22.6%)

497 (21.4%)

$5.3 – 11.7

1350 (25.3%)

784 (24.2%)

956 (25.7%)

574 (24.7%)

$11.8 – 26.7

1354 (25.4%)

855 (26.4%)

957 (25.8%)

619 (26.6%)

$26.8 – 538.8

1378 (25.8%)

872 (27%)

965 (26%)

634 (27.3%)

P<0.0001

P<0.0001

P<0.0001

P<0.0001

Number of Clinic Visit During the Study Period (During 18 months)
0–6

1480 (27.8%)

770 (23.8%)

914 (24.6%)

495 (21.3%)

7–9

1309 (24.5%)

743 (23%)

883 (23.8%)

499 (21.5%)

10 – 13

1277 (24%)

801 (24.8%)

931 (25.1%)

599 (25.8%)

14- 76

1266 (23.7%)

919 (28.4%)

988 (26.6%)

731 (31.5%)

P<0.0001

P<0.0001

P<0.0001

P<0.0001

Level of Adherence (Medication Possession Rate %)
90 – 100

3429 (64.3%)

2111 (65.3%)

2457 (66.1%)

1545 (66.5%)

80 – 89

395 (7.4%)

252 (7.8%)

274 (7.4%)

185 (8%)

70 – 79

382 (7.2%)

209 (6.4%)

252 (6.8%)

157(6.8%)

0 – 69

1126 (21.1%)

661 (20.4%)

733 (19.7%)

437 (18.8%)

P<0.0001

P<0.0001

P<0.0001

P<0.0001

*P-value according to the chi-square test.
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Table 4: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for SCR
Testing According to Patient Characteristics
Beta

Adjusted Odds

95% CI Low

95% CI High

0.600

1.141

Ratios
Age
Cat 1

-0.1891

0.828

Cat 2

N/A

N/A

Cat 3

0.8698

2.386

2.134

2.688

Cat 4

1.3880

4.007

3.292

4.877

Cardio-Disease

0.1837

1.202

1.065

1.356

Nephropathy

0.4101

1.507

1.242

1.828

Clinic Visit1

-0.3317

0.718

0.629

0.819

Clinic Viist2

N/A

N/A

Clinic Visit3

0.2537

1.289

1.117

1.487

Clinic Viist4

0.3979

1.489

1.287

1.722

0.906

1.316

Comorbidity

Health Utilization

Medication Adherence Level
MPR1

0.0882

1.092

MPR2

N/A

N/A

MPR3

-0.1003

0.905

0.704

1.161

MPR4

-0.0848

0.919

0.749

1.127
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Table 5: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for CBC or
B12 Testing According to Patient Characteristics
Beta

Odd Ratios

95% CI Low

95% CI High

Cat 1

0.0104

1.010

0.734

1.391

Cat 2

N/A

N/A

Cat 3

0.7276

2.070

1.858

2.306

Cat 4

1.1387

3.123

2.612

3.733

0.1402

1.151

1.042

1.270

0.4101

1.507

1.242

1.828

Clinic Visit1

-0.2918

0.747

0.654

0.853

Clinic Visit2

N/A

N/A

Clinic Visit3

0.2525

1.287

1.118

1.482

Clinic Visit4

0.5609

1.752

1.519

2.021

Age

Gender
Female
Comorbidity
Nephropathy
Health Utilization
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Table 6: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for HgbA1C
Testing According to Patient Characteristics
Beta

Odd Ratios

95% CI Low

95% CI High

Cat 1

0.1077

1.114

0.796

1.558

Cat 2

N/A

N/A

Cat 3

0.9795

2.663

2.323

3.054

Cat 4

2.1142

8.283

5.816

11.797

0.1352

1.145

1.020

1.285

0.1803

1.198

1.036

1.384

0.3207

1.378

1.080

1.758

Clinic Visit1

-0.3865

0.679

0.587

0.787

Clinic Visit2

N/A

N/A

Clinic Visit3

0.2094

1.233

1.038

1.465

Clinic Visit4

0.1677

1.183

0.995

1.406

Age

Gender
Female
Insulin Use
Insulin Use
Comorbidity
Nephropathy
Health Utilization
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Table 7: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for Optimal
Testing According to Patient Characteristics
Beta

Odd Ratios

95% CI Low

95% CI High

Cat 1

-0.0939

0.910

0.625

1.326

Cat 2

N/A

N/A

Cat 3

0.8010

2.228

1.983

2.503

Cat 4

1.1644

3.204

2.685

3.823

Cardio-Disease

0.1738

1.190

1.053

1.344

Nephropathy

0.4439

1.559

1.298

1.872

Respiratory

0.1865

1.205

1.040

1.396

Mental Disease

0.1775

1.194

1.030

1.384

Clinic Visit1

-0.2568

0.774

0.667

0.898

Clinic Visit2

N/A

N/A

Clinic Visit3

0.3430

1.409

1.212

1.638

Clinic Visit4

0.6602

1.935

1.664

2.250

0.744

1.104

Age

Comorbidity

Health Utilization

Medication Adherence Level
MPR1

-0.0982

0.906

MPR2

N/A

N/A

MPR3

-0.2077

0.812

0.621

1.063

MPR4

-0.2633

0.769

0.617

0.957
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